跳转至内容
Merck
CN
  • Opioid prescribing patterns after Mohs micrographic surgery and standard excision: a survey of American Society for Dermatologic Surgery members and a chart review at a single institution.

Opioid prescribing patterns after Mohs micrographic surgery and standard excision: a survey of American Society for Dermatologic Surgery members and a chart review at a single institution.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] (2014-07-16)
Kalynne Harris, Scott Calder, Brooke Larsen, Keith Duffy, Glen Bowen, Payam Tristani-Firouzi, Michael Hadley, Justin Endo
摘要

Little is known about postoperative opioid prescribing patterns among dermatologic surgeons. To better understand postoperative opioid prescribing patterns among dermatologic surgeons in the United States. Two-part analysis consisting of a retrospective chart review of 233 dermatologic surgery patients at a single institution and an e-mail survey of American Society for Dermatologic Surgery (ASDS) members. (1) Retrospective review: 35% (82/233) of the patients received an opioid prescription. Larger defect size, repair of the defect, perioral and nasal site, and surgeon A or B performing surgery predicted opioid prescription. (2) E-mail survey: 556 ASDS members practicing within the United States responded. Sixty-four percent (357/556) reported prescribing opioids after ≤10% of cases. Surgeons younger than 55 years old, male surgeons, and surgeons in the southern and western United States were more likely to prescribe opioids after >10% of cases. Seventy-six percent (397/520) believed patients used ≤50% of the opioid pills prescribed. The retrospective review suggests that opioid prescribing is predicted by characteristics of the surgery (i.e., size, defect repair type, and anatomic location) and characteristics of the surgeon (i.e., age, sex, and practice location) with significant heterogeneity in prescribing habits. The national survey results raise the possibility that patients might not take all prescribed opioid pills after dermatologic surgery. Further investigation is warranted to determine how patients are actually using prescription pain pills to balance pain control with patient safety.

材料
产品编号
品牌
产品描述

Supelco
对乙酰氨基酚, Pharmaceutical Secondary Standard; Certified Reference Material
USP
对乙酰氨基酚, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
对乙酰氨基酚, BioXtra, ≥99.0%
Sigma-Aldrich
对乙酰氨基酚, meets USP testing specifications, 98.0-102.0%, powder
Sigma-Aldrich
对乙酰氨基酚, analytical standard
扑热息痛, European Pharmacopoeia (EP) Reference Standard
Supelco
醋氨酚 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®